Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 13, 2002

View Archived Issues

Posaconazole effective against Aspergillus fumigatus in vitro and in vivo

Antiproliferative effects of selenomethionine in human prostate cancer cells

MT-100 well tolerated over one-year period

GenOdyssee's interferon variants show preclinical potential in hepatitis C and cancer

Pro-Pharmaceuticals to advance Davanat-1 into clinic in fourth quarter

Diacrin and Terumo sign muscle cell transplantation technology agreement for Japan

Cubist and Gilead's European commercialization agreement for Cidecin terminated

Cytotoxicity of CHS-828 enhanced in PARP-1-deficient mouse fibroblasts

Melacine rights return to Corixa

Herbal complex safe and effective for the treatment of IBS

Cardioprotective effect and mechanisms of Bay-11-7085 explored

PARS (PARP) activation implicated in autoimmune islet beta-cell destruction in NOD mice

Ezetimibe + statin effective and safe in hypercholesterolemic patients with type 2 diabetes

Potent, well-tolerated PDE4 inhibitor with suitable PK profile selected for development at Merck

Selective inverse agonist at GABA-A alpha5 receptor subtype enhances cognition in rats

Milnacipran phase II trial in FMS completes enrollment ahead of schedule

Avastin fails to meet primary endpoint in phase III metastatic breast cancer trial

Considerable progress reported by Xenova in first six months of 2002

Novel antibacterial carbapenems prepared and tested at Banyu

New FTase inhibitors for cancer and other conditions claimed by Servier

Wyeth and ArQule present novel inhibitors of Abeta production

New NPY receptor modulators and their use in obesity, diabetes, etc.

Antiprotozoal and antiretroviral compounds identified by French researchers

Akzo Nobel designs new GABA-A modulators for use as sedatives, analgesics

Novel agents for stimulating melanocyte proliferation covered by BTG patent

Popular Stories

Today's news in brief
BioWorld
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 17, 2026